Page 297 - Drug Class Review
P. 297
Drug Effectiveness Review Project
Alzheimer Drugs Authors: Wood et al. 69 Year: 1994 Country: UK Shire Pharmaceuticals and Parke-Davis Research Laboratories To determine whether oral TAC improves the symptoms of patients with mild to moderate AD Study design: RCT Setting: Multi-center (memory and psychogeriatric clinics) Sample size: 154 placebo tacrine N/A 80 mg/d 12 weeks 12 weeks 76 78 AD diagnosed by NINCDS/ADRDA; MMSE > 10; CDRS of 1 or 2 Evidence of concurrent illness (cerebral infarction, including evidence on CT scan, hepatic disease, clinical depression or other psychi
Final Report Update 1 Adverse Events STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
